Proposed removal of low volume or discontinued substances from the Revised In Commerce List

Official title: Proposed Removal of Low Volume or Discontinued Substances from the Revised In Commerce List

Health Canada

September 2020

Cat. No.: En14-407/2-2020E-PDF
ISBN 978-0-660-34390-7

Synopsis

Since September 14, 2001, new substances used in products regulated under the Food and Drugs Act (F&DA) have been subject to the New Substances Notification Regulations (Chemicals and Polymers) [NSNR(C&P)] and the New Substances Notification Regulations (Organisms) under the Canadian Environmental Protection Act, 1999 (CEPA). Prior to this date, substances used in products regulated under the F&DA were added to two different lists:

Unlike new substances that entered the Canadian market from September 14, 2001 onward for use in products regulated under the F&DA, these R-ICL substances, although subject to the NSNR, have not been requested for notification under the NSNR to date by matter of interim policy. However, Health Canada and Environment and Climate Change Canada may take appropriate action under CEPA at any time when they consider a R-ICL substance to pose a risk to human health or the environment.

As part of the Chemicals Management Plan (CMP), Health Canada has prioritized substances on the R-ICL to identify those that require further evaluation to determine whether they present a risk to human health or the environment. The scope of the R-ICL prioritization is limited to the use of substances in F&DA regulated products.

Prioritization was used to inform a subset of R-ICL substances for inclusion in a mandatory survey pursuant to section 71 of CEPA to obtain data on their recent commercial status in Canada. This survey was published in the Canada Gazette, Part I in January 2017 and contained 675 R-ICL substances that were listed in Part 4 of Schedule 1 of the survey. The scope of information gathering was limited to quantities and use patterns in F&DA product applications. The 100 kg/yr reporting threshold of the survey aligns with the 100 kg/yr minimum reporting requirement of the NSNR(C&P). Based on the results of the survey, 544 substances listed on the R-ICL were not reported as currently being imported or manufactured for use in F&DA products, or are potentially in use but at annual volumes below the NSNR triggers for reporting. These substances are listed in Appendix A of the present document.

In addition to the 544 substances mentioned above, 125 substances on the R-ICL not included in the above-mentioned mandatory survey were identified in Health Canada records as active pharmaceutical ingredients that have been discontinued, or have never been marketed, or have been approved for limited use such as substances used in research or provided through Health Canada’s Special Access Programme. These substances are listed in Appendix B of the present document.

Recent commercial status was used as an indicator to identify R-ICL substances that would be less likely to cause harm to human health or the environment as a result of their limited anticipated exposure potential. The 544 and 125 R-ICL substances listed in Appendices A and B, respectively, are consequently proposed to be removed from the R-ICL. This proposed removal does not preclude a more fulsome consideration of the exposure and risk of these substances under other CEPA initiatives. If removed, these substances would continue to be subject to the NSNR.

1. Introduction

The Canadian Environmental Protection Act, 1999 (CEPA) (Canada 1999) is considered the cornerstone of the Government of Canada's environmental legislation. Since September 14, 2001, new substances used in products regulated under the F&DA have been subject to the New Substances Notification Regulations (Chemicals and Polymers) [NSNR(C&P)] and the New Substances Notification Regulations (Organisms) (Canada 2005a, 2005b) of CEPA.

Prior to this date, substances used in products regulated under the F&DA were added to two different lists:

Unlike new substances that entered the Canadian market from September 14, 2001 onward for use in products regulated under the F&DA, these R-ICL substances, although subject to the NSNR, have not been requested for notification under the NSNR to date by matter of interim policy. Health Canada and Environment and Climate Change Canada may take appropriate action under CEPA at any time when they consider a R-ICL substance to pose a risk to human health or the environment.

The R-ICL contains substances used in a wide variety of applications including pharmaceuticals, medical devices, veterinary drugs, biologics (such as vaccines), natural health products, cosmetics, and food additives. The R-ICL was initially compiled from Health Canada records in 2001 and subsequently refined through a substance identity verification exercise. Substances were also added to the list through industry nominations, and the list has been periodically updated to reflect changes. In November 2019, the final nomination period to the R-ICL closed and as of March 2020 the R-ICL contains approximately 2,700 substances.

In 2016, under the Chemicals Management Plan (CMP), Health Canada prioritized the approximately 3,500 substances that were on the R-ICL at the time to identify those substances that require assessment to determine if they pose a significant risk to the environment or to human health. Identification of substances as lower priority or requiring no further consideration in the context of the R-ICL prioritization exercise was based on readily available hazard and exposure information. Prioritization of substances on the R-ICL resulted in approximately 25% of them being prioritized for further evaluation, while the remaining 75% were of reduced priority in the context of the R-ICL, including many of which were on the DSL. Those substances on the DSL have been deleted from the R-ICL to remove this redundancy. Reduced priority does not preclude actions being taken under other CEPA initiatives. A detailed document describing the approach to R-ICL prioritization was published on the CMP website on November 27, 2015 (Health Canada 2019b).

During prioritization of the R-ICL, 675 substances potentially used in products subject to the F&DA, were prioritized for further consideration based on an indication of hazard for human or environmental health and limited information on exposure which could mitigate those concerns. These 675 substances were included in Part 4 of Schedule 1 of a mandatory survey pursuant to section 71 of CEPA published in the Canada Gazette, Part I, in January 2017. The intent of this survey was to collect data on the commercial status of these substances to inform exposure potential. A 100 kg/yr reporting threshold was selected for this survey and it aligns with the 100 kg/yr minimum reporting requirement for Schedule 4 of the NSNR(C&P). The scope of information gathering was limited to quantities and use patterns for F&DA product applications. Based on the available information, 544 R-ICL substances were not reported as being manufactured or imported in Canada in F&DA product applications above the 100 kg/yr reporting threshold. These 544 R-ICL substances are identified in Appendix A.Footnote 1

In addition to the substances identified in Appendix A, up to 125 substances on the R-ICL that had not been included in the above-mentioned mandatory survey were identified in Health Canada records as active pharmaceutical substances that have been discontinued, have never been marketed, or have been approved with limited use in Canada; for example, this could include substances used in research or provided through Health Canada’s Special Access Programme (Health Canada 2019c) . These 125 R-ICL substances are listed in Appendix B.

Recent commercial status was used as an indicator to identify R-ICL substances that would be less likely to cause harm to human health or the environment as a result of their limited anticipated exposure potential. The 544 and 125 R-ICL substances listed in Appendices A and B, respectively, are consequently proposed to be removed from the R-ICL. This proposed removal does not preclude a more fulsome consideration of the exposure and risk of these substances under other CEPA initiatives. If removed, these substances would continue to be subject to the NSNR.  The Chemical Abstracts Service Registry NumbersFootnote 2 (CAS RN) as well as the substance names (CAS names) are listed in the Appendices.

2. Assessment of commercial activity in Canada of substances on the Revised In Commerce List

2.1 Section 71 survey - Inventory update

In January 2017, a mandatory survey pursuant to section 71 of CEPA was published. The purpose of this survey was to collect more recent information on the commercial status of the substances in Canada (Canada Gazette 2017). More recent information for substances on the R-ICL was critical to support priority setting and decision making. The government was seeking further information on 675 R-ICL substances on Part 4 of Schedule 1 of the survey. The scope of the survey for R-ICL substances was limited to use in F&DA products, and information requirements pertained to use patterns and quantities in use.

Regulated parties that imported or manufactured substances listed in Part 4 of the section 71 notice at a total quantity greater than 100 kg/yr during either the 2014 or 2015 calendar year were required to respond to the survey. Figure 3 from the January 2017 section 71 notice summarizes the reporting requirements for these R-ICL substances, and is replicated in Figure 1 (Environment and Climate Change Canada 2017).

Figure 1: Reporting diagram for each substance listed in Part 4 of the section 71 survey
Long description

The figure provides a schematic description of the reporting requirements for Notice with respect to substances included as part of the 2017 Inventory Update using a flow diagram. The diagram is composed of multiple rectangular and oval boxes that are connected with unidirectional arrows.

  1. Starting from the top part of the diagram, the first box asks whether you need to report for Part 4 substances. If you want to know if you need to report for a Part 4 substance, you are directed to the second box.
  2. The second box asks whether the substance was a cosmetic, food, therapeutic product or natural health product subject to the Food and Drugs Act, or if it was contained in such a product, or intended to be a component in such a product. If your answer is yes, then you are directed to the third and fourth boxes. If your answer is no, then you are directed to the sixth box.
  3. The third box asks whether you imported the substance in 2014 or 2015. If your answer is yes, then you are directed to the fifth box. If your answer is no, then you are directed to the sixth box.
  4. The fourth box asks if you manufactured the substance in 2014 or 2015. If your answer is yes, then you are directed to the fifth box. If your answer is no, then you are directed to the sixth box.
  5. The fifth box asks whether the quantity of substance imported or manufactured was greater than one hundred kilograms for 2014 or 2015. If your answer is yes, then you are directed to the seventh box. If your answer is no, then you are directed to the sixth box.
  6. The sixth box informs you that you do not have a legal obligation to report for this activity and it directs you to the eighth and ninth box.
  7. The seventh box asks whether you met all of the above criteria for 2015. If your answer is no, then you are directed to the tenth box. If your answer is yes, then you are directed to the eleventh box.
  8. The eighth box encourages you to submit a Declaration of Non-Engagement if you have no involvement with a reportable substance.
  9. The ninth box encourages you to submit a Declaration of Stakeholder Interest (for voluntary data) if you have a past, current or future interest for a reportable substance.
  10. The tenth box informs you that you have a legal obligation to report for this activity for 2014.
  11. The eleventh box informs you that you have a legal obligation to report for this activity for 2015.

Based on the available information, 544 R-ICL substances, which are listed in Appendix A, were identified as not being manufactured or imported in Canada, or reported quantities in F&DA product applications were less than 100 kg/yr. These 544 substances are, therefore, candidates for removal from the R-ICL.    

2.2 Identification of Discontinued Pharmaceuticals

Various internal and external sources of information were used to identify 125 substances on the R-ICL, listed in Appendix B, as active pharmaceutical substances used in products which have been discontinued, never marketed, or approved with limited use in Canada. These sources were considered for pharmaceutical substances that had not been included in Part 4 of the 2017 section 71 notice (Canada Gazette 2017). These included:

3. Conclusion

Listing on the R-ICL facilitates interim management of new substances used in F&DA regulated products introduced to the Canadian market between January 1, 1987 and September 13, 2001. The 544 R-ICL substances listed in Appendix A are substances that are of low volume based on results from a 2017 section 71 notice. The 125 active pharmaceutical substances listed in Appendix B are currently shown in Health Canada’s records as discontinued, not marketed, or approved for limited use in Canada. Given their limited anticipated exposure potential, the 544 and 125 R-ICL substances listed in Appendices A and B, respectively, are considered less likely to cause harm to human health and the environment. They are consequently proposed to be removed from the R-ICL. This proposed removal does not preclude a more fulsome consideration of the exposure and risk of these substances under other CEPA initiatives. If removed, these substances would continue to be subject to the NSNR.

4. References

Canada. 1999. Canadian Environmental Protection Act, 1999. S.C. 1999, c.33. Canada Gazette Part III, vol. 22, no. 3. 

Canada.  2005a.  New Substances Notification Regulations (Chemicals and Polymers).

Canada. 2005b. New Substances Notification Regulations (Organisms).

Canada Gazette. 2017. Vol. 151, No. 2 – January 14, 2017.

Environment and Climate Change Canada.  2017.  Guidance for responding to the Notice with respect to substances included as part of the 2017 Inventory Update.

Health Canada. 2019a. About the Revised In Commerce List (R-ICL).

Health Canada. 2019b. Results of the prioritization of the Revised In Commerce List

Health Canada. 2019c. Health Canada Special Access Programme.

Health Canada.  2019d. Drug Product Database.

Appendix A

Substances proposed for removal from the R-ICL based on results of a mandatory survey pursuant to section 71 of the Canadian Environmental Protection Act, 1999 which indicate that these substances were not manufactured or imported above the reporting threshold of 100 kg/yr in either the 2014 or 2015 calendar year in F&DA regulated products

The Chemical Abstracts Service (CAS) Registry Number (CAS RN)

Substance name

53-43-0

Androst-5-en-17-one, 3-hydroxy-, (3β)-

60-31-1

Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, chloride

66-40-0

Ethanaminium, N,N,N-triethyl-

68-05-3

Ethanaminium, N,N,N-triethyl-, iodide

79-17-4

Hydrazinecarboximidamide

85-19-8

Methanone, (5-chloro-2-hydroxyphenyl)phenyl-

85-70-1

1,2-Benzenedicarboxylic acid, 2-butoxy-2-oxoethyl butyl ester

87-18-3

Benzoic acid, 2-hydroxy-, 4-(1,1-dimethylethyl)phenyl ester

91-68-9

Phenol, 3-(diethylamino)-

94-43-9

Mercury, (benzoato-O)phenyl-

95-84-1

Phenol, 2-amino-4-methyl-

97-18-7

Phenol, 2,2'-thiobis[4,6-dichloro-

99-57-0

Phenol, 2-amino-4-nitro-

102-29-4

1,3-Benzenediol, monoacetate

102-98-7

Mercurate(2-), [orthoborato(3-)-κO]phenyl-, hydrogen (1:2)

104-98-3

2-Propenoic acid, 3-(1H-imidazol-4-yl)-

116-38-1

Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-, chloride (1:1)

122-11-2

Benzenesulfonamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)-

123-78-4

4-Octadecene-1,3-diol, 2-amino-, (2S,3R,4E)-

141-02-6

2-Butenedioic acid (E)-, bis(2-ethylhexyl) ester

141-86-6

2,6-Pyridinediamine

141-94-6

5-Pyrimidinamine, 1,3-bis(2-ethylhexyl)hexahydro-5-methyl-

142-55-2

2-hydroxypropyl laurate

145-13-1

Pregn-5-en-20-one, 3-hydroxy-, (3β)-

148-79-8

1H-Benzimidazole, 2-(4-thiazolyl)-

153-61-7

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[2-(2-thienyl)acetyl]amino]-, (6R,7R)-

306-94-5

Naphthalene, octadecafluorodecahydro-

362-74-3

Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate

500-38-9

1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-

501-30-4

4H-Pyran-4-one, 5-hydroxy-2-(hydroxymethyl)-

508-02-1

Olean-12-en-28-oic acid, 3-hydroxy-, (3β)-

518-40-1

Benzoic acid, 2-(6-hydroxy-4,5-diiodo-3-oxo-3H-xanthen-9-yl)-

522-48-5

1H-Imidazole, 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-, monohydrochloride

522-51-0

Quinolinium, 1,1'-(1,10-decanediyl)bis[4-amino-2-methyl-, dichloride

530-43-8

Hexadecanoic acid, (2R,3R)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl ester

538-02-3

Cyclopentaneethanamine, N,α-dimethyl-, hydrochloride

556-38-7

Pentanoic acid, zinc salt

557-61-9

1-Octacosanol

576-55-6

Phenol, 2,3,4,5-tetrabromo-6-methyl-

594-45-6

Ethanesulfonic acid

603-85-0

Phenol, 2-amino-3-nitro-

611-75-6

Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-, monohydrochloride 

660-27-5

Acetic acid, dichloro-, compd. with N-(1-methylethyl)-2-propanamine (1:1)

719-59-5

Methanone, (2-amino-5-chlorophenyl)phenyl-

820-66-6

1-Octadecanaminium, N-(carboxymethyl)-N,N-dimethyl-, hydroxide, inner salt

832-01-9

2-Propenoic acid, 3-(4-methoxyphenyl)-, methyl ester

865-44-1

Iodine chloride (ICl3)

866-82-0

1,2,3-Propanetricarboxylic acid, 2-hydroxy-, copper(2++) salt (1:2)

1093-16-9

Spiro[naphthalene-2(1H),2'-oxirane]-1-propanol, α-ethenyloctahydro-α,5,5,8a-tetramethyl-

1112-38-5

Phosphorothioic acid, O,O-dimethyl ester

1314-84-7

Zinc phosphide (Zn3P2)

1315-04-4

Antimony sulfide (Sb2S5)

1317-26-6

Aluminum magnesium hydroxide (AlMg2(OH)7), monohydrate

1319-53-5

Malachite (Cu2(CO3)(OH)2)

1322-14-1

10-Undecenoic acid, calcium salt

1399-80-0

Benzenedimethanaminium, ar-dodecyl-ar,N,N,N,N',N',N'-heptamethyl-, dichloride, mixt. with ar-dodecyl-ar,N,N,N-tetramethylbenzenemethanaminium chloride

1463-95-2

Pyridinium, 2-[2-[(5-bromo-2-pyridinyl)amino]ethenyl]-1-ethyl-6-methyl-, iodide (1:1)

1553-41-9

5,8,11,14,17-Eicosapentaenoic acid

1570-64-5

Phenol, 4-chloro-2-methyl-

1641-17-4

Methanone, (2-hydroxy-4-methoxyphenyl)(4-methylphenyl)-

1778-02-5

Pregn-5-en-20-one, 3-(acetyloxy)-, (3β)-

1929-30-2

2-Propenoic acid, 3-(4-methoxyphenyl)-, ethyl ester

1976-28-9

3-Pyridinecarboxylic acid, aluminum salt (3:1)

2016-45-7

1-Hexadecanamine, N,N-dimethyl-, hydrochloride (1:1)

2040-10-0

Ethanone, 1-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]-

2136-71-2

Ethanol, 2-(hexadecyloxy)-

2180-18-9

Acetic acid, manganese salt

2224-49-9

Dodecanoic acid, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)

2315-66-4

3,6,9,12,15,18,21,24,27-Nonaoxanonacosan-1-ol, 29-[4-(1,1,3,3-tetramethylbutyl)phenoxy]-

2370-64-1

Dodecanoic acid, 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl ester

2420-29-3

3,6,9,12,15,18-Hexaoxahexatriacontan-1-ol

2487-40-3

6H-Purin-6-one, 1,2,3,7-tetrahydro-2-thioxo-

2565-36-8

Ethanol, 2,2'-[methylenebis(oxy)]bis-

2568-33-4

1, 3-Butanediol, 3-methyl

2638-43-9

3,6,9,12,15,18,21-Heptaoxatricosan-1-ol, 23-[4-(1,1,3,3-tetramethylbutyl)phenoxy]-

2748-88-1

Pyridinium, 4-methyl-1-tetradecyl-, chloride

2784-94-3

Ethanol, 2,2'-[[4-(methylamino)-3-nitrophenyl]imino]bis-

2835-98-5

Phenol, 2-amino-5-methyl-

2835-99-6

Phenol, 4-amino-3-methyl-

2919-66-6

Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-16-methylene-

2944-65-2

Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, iron(2+) salt (1:1)

3069-40-7

Silane, trimethoxyoctyl-

3184-65-4

Phenol, 4-chloro-2-(phenylmethyl)-, sodium salt

3251-56-7

Phenol, 2-methoxy-4-nitro-

3305-68-8

9-Octadecen-1-ol, phosphate (3:1), (9Z,9'Z,9''Z)-

3374-30-9

Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl(phenylmethyl)amino]phenyl](5-hydroxy-2,4-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-, hydroxide, inner salt, calcium salt (2:1)

3397-16-8

L-Glutamic acid, N-(1-oxooctadecyl)-

3520-90-9

3,6,9,12,15,18,21-Heptaoxatricosan-1-ol, 23-(4-octylphenoxy)-

3521-84-4

D-Glucitol, 1-deoxy-1-(methylamino)-, 3,3'-[(1,6-dioxo-1,6-hexanediyl)diimino]bis[2,4,6-triiodobenzoate] (2:1) (salt)

3564-09-8

2,7-Naphthalenedisulfonic acid, 3-hydroxy-4-[2-(2,4,5-trimethylphenyl)diazenyl]-, sodium salt (1:2)

3599-32-4

1H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt

4316-73-8

Glycine, N-methyl-, monosodium salt

4372-02-5

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 4',5'-dibromo-3',6'-dihydroxy-, sodium salt (1:2)

4478-97-1

3,6,9,12,15-Pentaoxahentriacontan-1-ol

4618-23-9

Benzoic acid, 2,3,4,5-tetrachloro-6-(2,4,5,7-tetrabromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)-, disodium salt

4861-19-2

Urea, phosphate (1:1)

4991-65-5

1,3-Benzoxathiol-2-one, 6-hydroxy-

5353-26-4

3,6,9,12-Tetraoxatriacont-21-en-1-ol, (Z)-

5697-02-9

1-naphthalenol, 2-methyl-, acetate

5725-96-2

Methanamine, N-hydroxy-N-methyl-

5836-69-1

Phosphinic amide, P,P-dibutyl-N,N-dipropyl-

5858-61-7

2,7-Naphthalenedisulfonic acid, 3-[[4-(acetylamino)phenyl]azo]-4-hydroxy-, disodium salt

5863-51-4

Benzenemethanaminium, N-[4-[(2-chlorophenyl)[4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylene]-3-methyl-2,5-cyclohexadien-1-ylidene]-N-ethyl-3-sulfo-, hydroxide, inner salt, sodium salt

5905-52-2

Propanoic acid, 2-hydroxy-, iron(2+) salt (2:1)

6159-41-7

10-Undecenoic acid, potassium salt (1:1)

6219-67-6

1,3-Benzenediamine, 4-methoxy-, sulfate

6219-69-8

1,3-Benzenediamine, 4-ethoxy-, sulfate

6273-99-0

Mercury, [μ-[orthoborato(2-)-κO:κO']]diphenyldi-

6358-53-8

2-Naphthalenol, 1-[(2,5-dimethoxyphenyl)azo]-

6371-76-2

2-Naphthalenecarboxylic acid, 3-hydroxy-4-(phenylazo)-, calcium salt (2:1)

6371-96-6

Butanamide, 2-[(4-methoxy-2-nitrophenyl)azo]-N-(2-methylphenyl)-3-oxo-

6505-30-2

Benzenemethanaminium, N-[4-[[4-(diethylamino)phenyl][4-[ethyl[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylene]-3-methyl-2,5-cyclohexadien-1-ylidene]-N-ethyl-3-sulfo-, hydroxide, inner salt, sodium salt

6548-12-5

Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl[(3-sulfophenyl)methyl]amino]phenyl](2-sulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-3-sulfo-, inner salt, barium salt (1:1)

6640-03-5

1-Tetradecanol, hydrogen phosphate

6966-09-2

Cyclohexanone, 2-(1-piperidinylmethyl)-, hydrochloride (1:1)

7091-57-8

8-Quinolinol, benzoate (salt)

7147-34-4

1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-tris(2-ethylhexyl)ester

7211-53-2

Docosanoic acid, potassium salt (1:1)

7230-93-5

Dodecanoic acid, aluminum salt (3:1)

7446-27-7

Phosphoric acid, lead(2++) salt (2:3)

7492-68-4

Carbonic acid, copper salt

7651-99-2

Phosphonic acid, [1,2-ethanediylbis[nitrilobis(methylene)]]tetrakis-, pentasodium salt

7789-46-0

Iron bromide (FeBr2)

7790-44-5

Stibine, triiodo-

8007-56-5

Aqua regia

9050-93-5

β-D-Glucan, (1→3)-, carboxymethyl ether, sodium salt

9065-63-8

Oxirane, methyl-, polymer with oxirane, butyl ether

10031-23-9

Radium bromide (RaBr2)

10031-59-1

Sulfuric acid, thallium salt

10101-63-0

Lead iodide (PbI2)

10124-48-8

Mercury amide chloride (Hg(NH2)Cl)

10124-49-9

Sulfuric acid, iron salt

10139-47-6

Zinc iodide (ZnI2)

10192-46-8

Boric acid (H3BO3), zinc salt (2:3)

10233-14-4

9-Octadecenoic acid (Z)-, 2-[2-(2-hydroxyethoxy)ethoxy]ethyl ester

10294-31-2

Gold iodide (AuI)

10294-70-9

Tin iodide (SnI2)

10326-21-3

Chloric acid, magnesium salt

10361-76-9

Peroxymonosulfuric acid, potassium salt (1:2)

10476-84-3

Octadecanoic acid, manganese salt (1:?)

10476-86-5

Strontium iodide (SrI2)

11092-32-3

Aluminum oxide (AlO2)

11108-73-9

Uranium alloy, base, U,Nb,Zr (Mulberry)

12018-01-8

Chromium oxide (CrO2)

12122-15-5

Nickel carbonate hydroxide (Ni5(CO3)2(OH)6)

12217-41-3

C.I. Basic Blue 22

12217-43-5

9,10-Anthracenedione, 1-amino-4-[[4-[(dimethylamino)methyl]phenyl]amino]-

12221-52-2

C.I. Basic Red 22

12222-04-7

C.I. Direct Blue 199

12640-40-3

Bismuth oxide

12651-23-9

Titanium hydroxide

12684-19-4

Lead iodide

13103-75-8

Benzenamine, N,N-dimethyl-4-(2-pyridinylazo)-

13408-62-3

Ferrate(3-), hexakis(cyano-κC)-, (OC-6-11)-

13429-07-7

2-Propanol, 1-(2-methoxypropoxy)-

13557-75-0

Dodecanoic acid, 2-(1-carboxyethoxy)-1-methyl-2-oxoethyl ester, sodium salt (1:1)

13682-92-3

Aluminum, (glycinato-N,O)dihydroxy-, (ß-4)-

13779-98-1

Plumbane, tetraiodo-

14452-57-4

Magnesium peroxide (Mg(O2))

14465-68-0

9,12,15-Octadecatrienoic acid, 1,1',1''-(1,2,3-propanetriyl) ester, (9Z,9'Z,9''Z,12Z,12'Z,12''Z,15Z,15'Z,15''Z)-

14639-25-9

2-Pyridinecarboxylic acid, chromium(3+) salt (3:1)

15763-02-7

Butanedioic acid, 2-hydroxy-, 1,4-dioctyl ester

15792-51-5

Benzenesulfonic acid, 2,5-dichloro-4-[4,5-dihydro-3-methyl-5-oxo-4-[[3-[(phenylamino)sulfonyl]phenyl]azo]-1H-pyrazol-1-yl]-, monosodium salt

15876-39-8

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one,2',4',5',7'-tetrabromo-3',6'-dihydroxy, aluminum salt (3:2)

15905-86-9

Nitric acid, uranium salt

16040-38-3

Phosphoric acid, lead salt

16508-79-5

2-Naphthalenecarboxylic acid, 3-hydroxy-4-(2-phenyldiazenyl)-, barium salt (2:1)

16508-80-8

Benzoic acid, 2-(2,4,5,7-tetrabromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)-, aluminum salt (1:?)

16561-29-8

Tetradecanoic acid, (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa[3,4]benz[1,2-e]azulen-9-yl ester

16693-53-1

Glycine, N-methyl-N-(1-oxododecyl)-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)

16824-78-5

Phenol, 2,4,6-trinitro-, calcium salt

17121-12-9

1,3,5,7,2,4,6,8-Tetroxatetraphosphocane, 2,4,6,8-tetrahydroxy-,2,4,6,8-tetraoxide,ion(4-)

17375-37-0

Carbonic acid, manganese salt

17619-86-2

Ethanol, 2-amino-, sulfite (salt)

17672-22-9

Phenol, 2-amino-6-methyl-

17879-97-9

Benzenepropanoic acid, 3-amino-α-ethyl-2,4,6-triiodo-, (R)-

17949-65-4

Zinc, bis(2-pyridinecarboxylato-κN1,κO2)-, (T-4)-

18089-54-8

Silanol, methyl-

18358-13-9

2-Propenoic acid, 2-methyl-, ion(1-)

18917-91-4

Aluminum, tris(2-hydroxypropanoato-O¹,O²)-

20636-48-0

3,6,9,12-Tetraoxatetradecan-1-ol, 14-(4-nonylphenoxy)-

20858-25-7

3,6,9,12-Tetraoxatetracosanoic acid

20882-75-1

9H-Xanthen-9-one, 1,2,8-trihydroxy-6-methoxy-

21034-17-3

Oxazolium, 3,4-dimethyl-2-[2-(phenylamino)ethenyl]-, iodide

21109-95-5

Barium sulfide (BaS)

21127-45-7

3,6,9,12,15-Pentaoxaheptacosanoic acid

21245-01-2

Benzoic acid, 4-(dimethylamino)-, 3-methylbutyl ester

22366-99-0

9,10-Anthracenedione, 1-[(3-aminopropyl)amino]-4-(methylamino)-

22801-45-2

9-Octadecenoic acid (9Z)-, 2-octyldodecyl ester

23059-38-3

Cyclohexanecarboxylic acid, 1,4-dimethyl-, methyl ester, cis-

23250-42-2

Cyclohexanecarboxylic acid, 1,4-dimethyl-, methyl ester (trans)

24292-52-2

2-Propen-1-one, 1-[4-[[6-O-(6-deoxy-α-2-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-, (E)-

24545-86-6

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-4',5'-dinitro-

24905-87-1

Ethanol, 2-[(4-amino-3-nitrophenyl)amino]-

25482-78-4

Peroxymonosulfuric acid, potassium salt

25709-83-5

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 2',4',5'-tribromo-3',6'-dihydroxy-

25709-84-6

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 2',4',7'-tribromo-3',6'-dihydroxy-

25852-45-3

Poly(oxy-1,2-ethanediyl), α-phosphono-ω-(dodecyloxy)-

26264-02-8

3,6,9,12-Tetraoxatetradecan-1-ol, 14-(nonylphenoxy)-

26538-44-3

1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-, [3S-(3R,7S)]-

26545-51-7

Benzamide, N,N-diethylmethyl-

26658-83-3

2-Propenoic acid, 2-methyl-, butyl ester, polymer with 2-(dimethylamino)ethyl 2-methyl-2-propenoate

26915-12-8

Benzenamine, ar-methyl-

26920-62-7

1-Docosanaminium, N-(carboxymethyl)-N,N-dimethyl-, inner salt

27177-03-3

3,6,9,12,15,18-Hexaoxaeicosan-1-ol, 20-(nonylphenoxy)-

27177-07-7

3,6,9,12,15,18,21,24,27-Nonaoxanonacosan-1-ol, 29-(octylphenoxy)-

27636-82-4

2,4-imidazolidinedione, (hydroxymethyl)-5,5-dimethyl-

27640-89-7

13-Docosenoic acid, (13Z)-13-docosen-1-yl ester, (13Z)-

28212-44-4

Poly(oxy-1,2-ethanediyl), α-(carboxymethyl)-ω-(4-nonylphenoxy)-

28261-54-3

Pyrrolidinone

28602-69-9

Diphosphoric acid, ammonium manganese(2+) salt (2:2:3)

28855-27-8

Benzenemethanaminium, ar-dodecyl-ar,N,N,N-tetramethyl-, chloride

31282-04-9

D-Streptamine, O-6-amino-6-deoxy-L-glycero-D-galacto-heptopyranosylidene-(1→2-3)-O-β-D-talopyranosyl-(1→5)-2-deoxy-N3-methyl-

31512-74-0

Poly[oxy-1,2-ethanediyl(dimethyliminio)-1,2-ethanediyl(dimethyliminio)-1,2-ethanediyl chloride (1:2)]

31846-06-7

Cyclohexanol, 3-(1,1-dimethylethyl)-, acetate

32310-26-2

Androstene

33239-19-9

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-4',5'-diiodo-, sodium salt (1:2)

33907-46-9

Octadecanoic acid, hydroxy-, 2-hydroxyethyl ester

33907-47-0

Octadecanoic acid, hydroxy-, monoester with 1,2-propanediol

34464-38-5

Isodecane

34769-44-3

1,3(2H,9bH)-Dibenzofurandione, 2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-, sodium salt (1:1)

34965-01-0

Pyrrolidine, 1-[2-(dodecyloxy)ethyl]-, hydrochloride

35602-69-8

Cholest-5-en-3-ol (3β)-, 3-octadecanoate

37220-90-9

Silicic acid, lithium magnesium salt

37222-66-5

Potassium peroxymonosulfate sulfate (K5(HSO5)2(HSO4)(SO4))

37286-92-3

Benzenesulfonic acid, ethenyl-, homopolymer, calcium salt

38480-64-7

1-Dodecanesulfonic acid, ion(1-)

38577-97-8

Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-4',5'-diiodo-

38621-51-1

Octadecanoic acid, 12-hydroxy-, monoester with 1,2-propanediol

38866-20-5

Morpholinium, 4-[3-[(9,10-dihydro-4-hydroxy-9,10-dioxo-1-anthracenyl)amino]propyl]-4-methyl-, methyl sulfate (1:1)

38886-21-4

Phenol, 2-methoxynitro-

38975-03-0

3,6,9,12,15-Pentaoxaheptacosanoic acid, sodium salt

39322-04-8

Chromium potassium oxide

39456-59-2

Phosphoric acid, mixt. with sodium fluoride (NaF)

40160-92-7

Poly(oxy-1,2-ethanediyl), α-(3-pentadecylphenyl)-ω-hydroxy-

40188-41-8

Octanenitrile, 3,7-dimethyl-

40738-57-6

2-Propenoic acid, ethenylidene ester, homopolymer

41080-66-4

Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-propanetriyltris[ω-[(1-oxooctadecyl)oxy]-

41669-40-3

Tetradecanoic acid, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)

41927-88-2

Sodium iodide (Na123I)

49625-21-0

Butanoic acid, 4-[[4-[[[(4-methoxy-2-nitrophenyl)amino]carbonyl]amino]benzoyl]amino]-2-oxo-

50545-60-3

Phenol, methyl-, tetrabromo deriv.

50610-28-1

Ethanol, 2-[(4-amino-2-chloro-5-nitrophenyl)amino]-

50800-85-6

Indium chloride (111InCl3)

50982-74-6

Ethanol, 2-(4-amino-3-nitrophenoxy)-

50994-40-6

1,4-Benzenediamine, sulfate (1:?)

51023-21-3

1H-Imidazolol, ethyldihydro[(9Z)-9-octadecen-1-yl]-

51192-09-7

Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with 1,2,3-propanetriol mono-9-octadecenoate (2:1), (Z)-

51311-89-8

Antimony iodide

51365-71-0

1,2-Benzenedicarboxamide, N,N'-dioctadecyl-

51513-58-7

6,10-Dodecadienal, 3,7,11-trimethyl-, (6E)-

51781-21-6

2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, hydrochloride (1:1)

51810-70-9

Zinc phosphide

51852-65-4

Poly(oxy-1,2-ethanediyl), α-[2-hydroxy-3-[(1-oxooctadecyl)oxy]propyl]-ω-hydroxy-

52557-98-9

Bicyclo[2.2.1]heptane-2-carboxylic acid, 3,3-dimethyl-

53171-04-3

1-Propanaminium, 2-hydroxy-N,N,N-trimethyl-3-[(1-oxododecyl)oxy]-, chloride

54590-52-2

Benzenesulfonic acid, 4-dodecyl-, compd. with 1-amino-2-propanol (1:1)

55837-20-2

4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-, rel-

55852-15-8

Propanoic acid, 2-hydroxy-, compd. with N-[3-(dimethylamino)propyl]-16-methylheptadecanamide (1:1)

55901-20-7

D2-Proline, 5-oxo-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)

55940-73-3

Benzoic acid, 2-hydroxy-, oxybis(methyl-2,1-ethanediyl) ester

56554-41-7

9,12,15-Octadecatrienoic acid, 2,3-dihydroxypropyl ester

56639-51-1

Aluminum, hydroxybis(tetradecanoato-κO)-

56827-95-3

1-Hexadecanol, phosphate (3:1)

57072-40-9

1,2,3-Propanetricarboxylic acid, 2-hydroxy-, chromium(3+) salt (1:?)

57524-53-5

Ethanol, 2-[(4-methoxy-2-nitrophenyl)amino]-

57834-50-1

Benzoic acid, 4-[[[[4-(ethoxycarbonyl)phenyl]amino]methylene]amino]-, ethyl ester

57934-97-1

2-Cyclohexene-1-carboxylic acid, 2-ethyl-6,6-dimethyl-, ethyl ester

57963-76-5

4a(2H)-Naphthalenol, octahydro-4,4,8a-trimethyl-,trans-

57963-77-6

cis-1,1,10-Trimethyl-9-decahydronaphthol

58855-36-0

Ethanol, 2,2'-iminobis-, compd. with α-sulfo-ω-(dodecyloxy)poly(oxy-1,2-ethanediyl) (1:1)

59056-93-8

Ethanone, 1-[(2R,3S)-1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl]-, rel-

59587-08-5

1,3-Dioxolo[4,5-g]quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo-, sodium salt (1:1)

59599-53-0

Benzoic acid, 2-hydroxy-, 2-(2-hydroxy-1-methylethoxy)-1-methylethyl ester

59599-58-5

Benzenesulfonic acid, 4-tridecyl-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)

59792-81-3

Aluminum, tris(5-oxo-L-prolinato-κN1,κO2)-

59820-63-2

2-[3-(methylamino)-4-nitrophenoxy]ethanol

59970-10-4

3,6,9,12-Tetraoxatriacontan-1-ol

60031-93-8

Cyclohexanemethanol, 4-ethenyl-α,α,4-trimethyl-3-(1-methylethenyl)-, acetate, [1R-(1α,3α,4β)]-

60662-14-8a

Indate(2-)-111In, [N,N-bis[2 [bis(carboxymethyl)amino]ethyl]glycinato(5-)]-, disodium

60684-33-5

2,5-Cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl)-5,6-dimethoxy-3-methyl-

60778-99-6

Sulfuric acid, aluminum magnesium salt

61692-77-1

2-Butenoic acid, 2-methyl-, 2-methylbutyl ester, (2Z)-

61693-08-1

Heptadecane, 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16-hexadecamethyl-

61702-44-1

1,4-Benzenediamine, 2-chloro-, sulfate (1:1)

61790-62-3

Fatty acids, coco, reaction products with N,N-dimethyl-1,3-propanediamine

61886-59-7

Benzenesulfonic acid, tridecyl-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)

62152-14-1

1-Propanesulfonic acid, 2-methyl-2-[(1-oxo-2-propen-1-yl)amino]-, ammonium salt (1:1), homopolymer

62406-73-9

6,10-Dioxaspiro[4.5]decane, 8,8-dimethyl-7-(1-methylethyl)-

62625-14-3

Phenol, 2-amino-6-chloro-4-nitro-, monohydrochloride

63084-98-0

Phenol, 4-amino-, sulfate (2:1) (salt)

63089-86-1

Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with D-glucitol (6:1), tetra-9-octadecenoate, (all-Z)-

64924-67-0

4(3H)-Quinazolinone, 7-bromo-6-chloro-3-[3-[(2R,3S)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-, monohydrobromide, rel-

65389-08-4

Indium-111In, tris(8-quinolinolato-κN1,κO8)-

65405-96-1

Nickel, [μ-[carbonato(2-)-κO:κO']]dihydroxydi-

66095-81-6

Ethanol, 2-[(2-methoxy-4-nitrophenyl)amino]-

66575-29-9

1H-Naphtho[2,1-b]pyran-1-one, 5-(acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-, [3R-(3-α,4a-β,5-β,6-β,6a-α,10-α,10a-β,10b-α)]-

66671-82-7

1,4-Benzenediamine, 2-methoxy-, sulfate (1:1)

67783-98-6

Formaldehyde, polymer with 4,4'-(1-methylethylidene)bis[phenol] and 2-methylphenol

67846-16-6

1-Propanaminium, N-ethyl-N,N-dimethyl-3-[(1-oxooctadecyl)amino]-, ethyl sulfate

67874-65-1

Propanoic acid, 3-mercapto-, 2,3-dihydroxypropyl ester

67914-69-6

1-Piperazinecarboxylic acid, 4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, ethyl ester, rel-

68015-98-5

1,3-Benzenediamine, 4-ethoxy-, sulfate (1:1)

68239-79-2

Phenol, 3-(ethylamino)-4-methyl-, sulfate (2:1) (salt)

68239-83-8

1,4-Benzenediamine, 2-nitro-, sulfate (1:1)

68239-84-9

Phenol, 3-(diethylamino)-, sulfate (2:1) (salt)

68391-32-2

2-Naphthalenaminium, 8-[(4-amino-3-nitrophenyl)azo]-7-hydroxy-N,N,N-trimethyl-, chloride

68413-33-2

Quaternary ammonium compounds, bis(2-​hydroxy-​C>10-​alkyl)​dimethyl, chlorides

68475-50-3

Aluminum, tris[5-amino-4-hydroxy-3-(phenylazo)-2,7-naphthalenedisulfonato(2-)]di-

68479-64-1

Butanedioic acid, 2-sulfo-, mono[2-[[(9Z)-1-oxo-9-octadecen-1-yl]amino]ethyl] ester, sodium salt (1:2)

68552-95-4

Fatty acids, vegetable-oil, ethoxylated

68797-65-9

1-Propanaminium, N-ethyl-N,N-dimethyl-3-[(1-oxodocosyl)amino]-, ethyl sulfate

68889-49-6

9-Octadecenoic acid (Z)-, 1,2,3-propanetriyl ester, polymer with α-hydro-ω-hydroxypoly(oxy-1,2-ethanediyl)

68890-92-6

Poly(oxy-1,2-ethanediyl), α-(3-carboxy-1-oxosulfopropyl)-ω-hydroxy-, ethers with lanolin alcs., disodium salts

68910-56-5

Quaternary ammonium compounds, di-C12-15-alkyldimethyl, chlorides

68915-25-3

Keratins, lauroyl

68929-04-4

1H-Imidazolium, 1-[2-(2-carboxyethoxy)ethyl]-1-(2-carboxyethyl)-4,5-dihydro-2-undecyl-, hydroxide, disodium salt

68935-40-0

1H-Indene-2-propanoic acid, 2,3-dihydro-1-oxo-5,6-bis(phenylmethoxy)-2-propyl-

68953-59-3

Ethanaminium, 2-amino-N-(2-aminoethyl)-N-(2-hydroxyethyl)-N-methyl-, N,N'-bis(hydrogenated tallow acyl) derivs., Me sulfates (salts)

68953-68-4

Aluminum, chloro propylene glycol complexes

69537-38-8

1-Propanaminium, 2-hydroxy-N,N,N-trimethyl-3-[(1-oxodocosyl)oxy]-, chloride (1:1)

70729-87-2

Isooctadecanoic acid, compd. with N,N-dimethyl-1-dodecanamine (1:1)

71060-72-5

Quaternary ammonium compounds, tri-C14-18-alkylmethyl, chlorides

71463-34-8

1H-Imidazolium, 1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-2-undecyl-, hydrogen sulfate (salt), monosodium salt

71735-79-0

13-Oxabicyclo[10.1.0]trideca-4,8-diene, trimethyl-

71812-38-9

Sorbitan, isooctadecanoate (2:3)

71850-81-2

1-Propanaminium, N-(carboxymethyl)-3-[(12-hydroxy-1-oxo-9-octadecenyl)amino]-N,N-dimethyl-, hydroxide, inner salt, [R-(Z)]-

71957-08-9

Cobalt, bis(D-gluconato-κO1,κO2)-,(T-4)-

72230-86-5

Terpenes and Terpenoids, cedarwood-oil, Texan, hydroxy, acetates

73772-45-9

1-Propanaminium, N-(carboxymethyl)-N,N-dimethyl-3-[(1-oxodecyl)amino]-, hydroxide, inner salt

73772-46-0

1-Propanaminium, N-(carboxymethyl)-N,N-dimethyl-3-[(1-oxooctyl)amino]-, hydroxide, inner salt

75018-70-1

Ethanesulfonic acid, 2-[[[[(3α,5β,7α,12α,20S)-3,7,12-trihydroxy-20-methylpregnan-21-yl]seleno-75Se]acetyl]amino]-

75911-79-4

Bicyclo[3.2.1]octan-8-ol, 1,5-dimethyl-, acetate

77851-07-1

2-Cyclohexene-1-carboxylic acid, 2,3,6,6-tetramethyl-, ethyl ester

77923-28-5

Cyclododecane, (2-methoxyethoxy)-

78509-74-7

1-(hexadecyloxy)octadecan-2-ol)

78616-98-5

Dodecanoic acid, 2-aminoethyl ester

79120-33-5

Litharge (PbO)

79702-63-9

Butanedioic acid, 2-sulfo-, mono[2-[[(9Z)-1-oxo-9-octadecen-1-yl]amino]ethyl] ester, sodium salt (1:2)

84366-81-4

Riboflavin 5'-(trihydrogen diphosphate), P'→5'-ester with adenosine, disodium salt

80435-42-3

Iron alloy, base, Fe 63-74,Cr 12.0-15.0,Ni 12.0-15.0,W 1.50-3.00,Mn 0-1.00,Si 0.30-0.80,C 0.35-0.50,Mo 0.20-0.50,P 0-0.045,S 0-0.030 (UNS S66009)

81783-01-9

6,8-Nonadien-3-one,2,4,4,7-tetramethyl-,oxime

81818-54-4

1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-

81907-73-5

3-Cyclopentene-1-acetic acid, 2,2,3-trimethyl-, ethyl ester

83615-24-1

Cholest-5-en-3-ol (3β)-, 3-isooctadecanoate

83763-47-7

Ethanol, 2-[(3-amino-4-methoxyphenyl)amino]-

83763-48-8

Ethanol, 2-[(3-amino-4-methoxyphenyl)amino]-, sulfate (1:1)

84041-77-0

Ethanol, 2,2'-[(2-nitro-1,4-phenylene)diimino]bis-

84563-62-2

Chitosan, hexanedioate (salt)

84605-12-9

13-Docosenoic acid, 13-docosenyl ester

84608-82-2

2-hydroxy-3-(oleoyloxy) propyl 5-oxo-L-prolinate

84642-57-9

Cyclopentanone, 2-[(3,3,5-trimethylcyclohexyl)acetyl]-

84753-08-2

1,3-bis(2-ethylhexyl)cyclohexane

84878-34-2

Isononanoic acid, octadecyl ester

85058-43-1

1-Piperazinecarboxylic acid, 4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, ethyl ester, rel-

85066-57-5

Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-(octadecyloxy)-

85252-25-1

Benzoic acid, 2-hydroxy-, isodecyl ester

85264-33-1

1H-Pyrazole-1-methanol, 3,5-dimethyl-

85765-48-6

Ethanol, 2-[4-[(2-aminoethyl)amino]-3-nitrophenoxy]-

86050-77-3

D-glucitol, 1-deoxy-1-(methylamino)-, [N,N-bis[2-[bis[(carboxy-κO)methyl]amino-κN]glycinato(5-)-κN,κO]gadolinate(2-) (2:1)

86419-69-4

1,2-Ethanediamine, N1-(5-methoxy-2-nitrophenyl)-, hydrochloride (1:1)

86481-08-5

Poly(oxy-1,2-ethanediyl), α, α'.-(1-methyl-1,2-ethanediyl)bis[ω-[[(9Z)-1-oxo-9-octadecenyl]oxy]-

88103-59-7

13-Docosenoic acid, 2-octyldodecyl ester, (13Z)-

90283-04-8

1-Dodecanaminium, N-[2-(dodecyloxy)-2-oxoethyl]-N,N-dimethyl-, chloride

90529-57-0

1-Propanaminium, 3-amino-N-ethyl-N,N-dimethyl-, N-soya acyl derivs., Et sulfates

90817-34-8

2,3-Pyridinediamine, 6-methoxy-N2-methyl-

91995-81-2

Fatty acids, C10-20 and C16-18-unsatd., reaction products with triethanolamine, di-Me sulfate-quaternized

92045-77-7

Petrolatum (petroleum), hydrotreated

92348-62-4

Octanoic acid, hydroxy-

92952-81-3

Phenol, 4-[(3-hydroxypropyl)amino]-3-nitro-

93385-13-8

Ethanol, 2-[2-[2-[2-(isohexadecyloxy)propoxy]ethoxy]ethoxy]-, acetate

93385-14-9

1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-triisohexadecyl ester

93507-51-8

1-Propanaminium, 3-[(2-hydroxy-1-oxopropyl)amino]-N,N,N-trimethyl-, chloride (1:1)

93841-25-9

Benzeneethanol, 2,5-diamino-, sulfate (1:1)

94158-13-1

Ethanol, 2,2'-[(4-amino-3-nitrophenyl)imino]bis-, monohydrochloride

94158-14-2

Ethanol, 2-(1,3-benzodioxol-5-ylamino)-, hydrochloride (1:1)

94201-62-4

Docosanoic acid, 2-hydroxy-1,3-propanediyl ester

94247-26-4

Tetradecyl isooctadecanoate

94277-32-4

1,2-Hexadecanediol, 1,1'-(hydrogen phosphate), monosodium salt

94333-50-3

1-Cyclohexene-1-carboxylic acid, 2-ethyl-3,6,6-trimethyl-, ethyl ester

94333-51-4

Cyclohexanecarboxylic acid, 6-ethylidene-2,2,5-trimethyl-, ethyl ester

94400-98-3

Naphth[2,3-b]oxirene, 1a,2,3,4,5,6,7,7a-octahydro-1a,3,3,4,6,6-hexamethyl-, (1aα,4α,7aα)-

95193-70-7

Amines, N-(C8-18 and C18-unsatd. alkyl)trimethylenedi-, reaction products with 2-chloroethanol and sodium chloroacetate

95193-83-2

1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts

95371-16-7

Sulfonic acids, C14-16-1-alkene, sodium salts

95576-89-9

1,2-Propanediol, 3-[(4-amino-2-chloro-5-nitrophenyl)amino]-

95576-92-4

1,2-Propanediol, 3,3'-[(2-chloro-5-nitro-1,4-phenylene)diimino]bis-

97375-39-8

C.I. Food Yellow 4:2

97862-76-5

Foots oil (petroleum), carbon-treated

97862-89-0

Paraffin waxes (petroleum), carbon-treated

97862-97-0

Petrolatum (petroleum), carbon-treated

97952-68-6

Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, salts with montmorillonite

99542-23-1

1-Propanaminium, N-ethyl-N,N-dimethyl-3-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]amino]-, ethyl sulfate

99610-72-7

Phenol, 2-[(2-hydroxyethyl)amino]-4,6-dinitro-

99948-86-4

2-[(dihydroxymethylsilyl)oxy]propionic acid

100418-33-5

Ethanol, 2-[(4-methyl-2-nitrophenyl)amino]-

100684-33-1

Petrolatum (petroleum), clay-treated

100684-38-6

Residual oils (petroleum), clay-treated solvent-dewaxed

100684-49-9

Slack wax (petroleum), carbon-treated

101831-37-2

Benzeneacetonitrile, 2,6-dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-

102868-96-2

Zinc, bis[N-(acetyl-κO)-L-methioninato-κO]-, (T-4)-

103622-85-1

3,6,9,12-Tetraoxatriacont-21-en-1-ol

103810-94-2

Methanone, diphenyl-, dihydroxy deriv.

104333-00-8

1,2-Propanediol, 3-[[2-nitro-4-(trifluoromethyl)phenyl]amino]-

104365-75-5

2-Propenoic acid, homopolymer, ester with 1,2,3-propanetriol

105859-93-6

Propanoic acid, 2,2-dimethyl-, tridecyl ester

105883-51-0

Copper, bis[N-(acetyl-κO)-L-methioninato-κO]-

105883-52-1

Cobalt, bis[N-(acetyl-κO)-L-methioninato-κO]-

106233-09-4

Poly(oxy-1,2-ethanediyl),α-hydro-ω-hydroxy-,mono-C16-18-alkyl ethers, phosphates

106392-12-5

Oxirane, 2-methyl-, polymer with oxirane, block

106631-38-3

1-Naphthalenepropanol, α-ethenyldecahydro-α,5,5,8a-tetramethyl-2-methylene-

108050-54-0

Tylosin, 4A-O-de(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)-20-deoxo-20-[(3R,5S)-3,5-dimethyl-1-piperidinyl]-

108347-90-6

Poly[oxy(methyl-1-,2-ethanediyl)], α-benzoyl-ω-(octadecyloxy)-

109423-22-5

Benzoic acid, 2-hydroxy-, 5-methyl-2-(1-methylethyl)cyclohexyl ester

109485-61-2

Nonane, 2,2,4,4,6,6,8-heptamethyl-

110332-91-7

Oxirane, methyl-, polymer with oxirane, monoacetate, isohexadecyl ether, block

113010-52-9

Benzoic acid, 4-amino-, ethyl ester, polymer with oxirane

113089-59-1

Collagens, hydrolyzates, reaction products with 3-chloro-2-hydroxy-N,N,N-trimethyl-1-propanaminium chloride

113507-06-5

Milbemycin B, 5-O-demethyl-28-deoxy-25-[(1E)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-(methoxyimino)-, (6R,23E,25S)-

113221-73-1

2-Naphthalenecarboxaldehyde, 5,6,7,8-tetrahydro-5,5,7,8,8-pentamethyl-

115340-78-8

1-Propanaminium, 3-amino-N-ethyl-N,N-dimethyl-, N-apricot-oil acyl derivs., Et sulfates

117704-25-3

Avermectin A1a, 25-cyclohexyl-5-O-demethyl-25-de(1-methylpropyl)-

119691-49-5

1-Eicosanol, 2-tetradecyl-

119831-19-5

Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with methyl D-glucopyranoside (4:1), dioctadecanoate

120066-54-8

Gadolinium, [10-[2-(hydroxy-κO)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-κN1,κN4,κN7,κN10,κO1,κO4,κO7]-

121546-77-8

Alcohols, C12-15 ethoxylate, sulfonate, sodium salt

121684-92-2

α-D-Glucopyranoside, β-D-fructofuranosyl, acetate dioctadecanoate

121734-19-8

1,3-Benzenediamine, 4-methoxy-, sulfate

121888-66-2

Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, benzoate lauryl sulfate, salts with bentonite

121888-67-3

Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, bis(hydrogenated tallow alkyl)dimethylammonium salt with hectorite

121888-68-4

Quaternary ammonium compounds, benzyl(hydrogenated tallow alkyl)dimethyl, stearates, salts with bentonite

123997-26-2

Avermectin B1, 4"-(acetylamino)-4"-deoxy-, (4"R)-

124046-05-5

Benzenemethanaminium, N-(3-aminopropyl)-N,N-dimethyl-, N-babassu-oil acyl derivs., chlorides

124046-40-8

Amides, wheat germ-oil, N-[3-(dimethylamino)propyl], lactates

125109-85-5

Benzenepropanal, β-methyl-3-(1-methylethyl)-

125804-04-8

Docosanoic acid, compd. with N-[3-(dimethylamino)propyl]docosanamide (1:1)

125804-08-2

Docosanoic acid, 2-octyldodecyl ester

125804-10-6

9,12-Octadecadienoic acid (9Z,12Z)-, dimer, compd. with (9Z,12Z)-N-[3-(dimethylamino)propyl]-9,12-octadecadienamide (1:1)

126506-93-2

1,3,2-Dioxastibolane-4,5-dicarboxylic acid, 2-hydroxy-, 2-oxide

126595-07-1

Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis-, homopolymer

127061-56-7

L-Ascorbic acid, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-YL hydrogen phosphate], potassium salt (1:1)

127311-98-2

1-Propanaminium, 3-[[(9Z,12R)-12-hydroxy-1-oxo-9-octadecenyl]amino]-N,N,N-trimethyl-, chloride

128973-71-7b

Siloxanes and Silicones, α-D-mannopyranuronoyloxy Me, hydroxy-terminated

128973-73-9

Siloxanes and Silicones, Me[1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)acetyl]oxy, hydroxy-terminated

128973-74-0

Siloxanes and Silicones, (2S-trans)-[[4-hydroxy-2-pyrrolidinyl)carbonyl]oxy] Me, hydroxyl-terminated

129496-10-2

 Milbemycin, oxime

129541-40-8

Tetradecanamide, N-[3-(dimethylamino)propyl]-, phosphate (1:1)

130291-58-6

2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester, homopolymer, compd. with bromomethane

130353-64-9

Quaternary ammonium compounds, coco alkyl(2,3-dihydroxypropyl)dimethyl, 3-ethers with cellulose 2-hydroxyethyl ether, chlorides

130381-02-1

Protein hydrolyzates, soya, [3-(dodecyldimethylammonio)-2-hydroxypropyl], chlorides

130381-04-3

Protein hydrolyzates, wheat germ, [3-(coco alkyldimethylammonio)-2-hydroxypropyl], chlorides

130381-05-4

Protein hydrolyzates, wheat germ, [3-(dimethyloctadecylammonio)-2-hydroxypropyl], chlorides

131044-77-4

Copper, N-acetyl-L-tyrosine hydroxy-terminated (S)-[2-(acetylamino)-3-(4-hydroxyphenyl)-1-oxopropoxy] Me siloxanes

131044-78-5

Copper, hydroxy-terminated Me (S)-[[(5-oxo-2-pyrrolidinyl) carbonyl]oxy] siloxanes 5-oxo-L-proline complexes

131216-83-6

Siloxanes and Silicones, 2-(acetylamino)-4-(methylthio)-1-oxobutyoxy Me, hydroxy-terminated

131410-48-5

Gadolinium, [5,8-bis[(carboxy-κO)methyl]-11-[2-(methylamino)-2-(oxo-κO)ethyl]-3-(oxo-κO)-2,5,8,11-tetraazatridecan-13-oato(3-)-κN5,κN8,κN11,κO13]-

131812-48-1

1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthalenyl)-

131812-49-2

Naphthalene, 7-(diethoxymethyl)-1,2,3,4-tetrahydro-1,1,2,4,4-pentamethyl-

131812-51-6

1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-, cis- 

131812-52-7

1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-, trans-

131812-67-4

1,3-Dioxolane, 2,4-dimethyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-

132467-76-6

1-Octadecanaminium, N-[2-hydroxy-3-[3-hydroxy-4-[(3-hydroxypropyl)amino]-2,2-dimethyl-4-oxobutoxy]propyl]-N,N-dimethyl-, chloride

133934-09-5

1-Propanaminium, 3-amino-N-(carboxymethyl)-N,N-dimethyl-, N-wheat-oil acyl derivs., inner salts

134112-42-8

1-Propanaminium, N-[2-(dodecyloxy)-2-oxoethyl]-N,N-dimethyl-3-[(1-oxoisooctadecyl)amino]-,chloride

135326-54-4

Propanol, (tetradecyloxy)-, acetate

136207-49-3

3,6,9,12,15-Pentaoxaheptatriacontan-1-ol

136505-01-6

2-Propenenitrile, homopolymer, hydrolyzed, block, reaction products with N,N-dimethyl-1,3-propanediamine

136920-08-6

1-Propanaminium, N-(3-aminopropyl)-2,3-dihydroxy-N,N-dimethyl-, N-coco acyl derivs., chlorides

137044-11-2

1-Propanaminium, 3-[2-(acetylamino)ethoxy]-N,N,N-trimethyl-, chloride

139247-28-2

Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-propanetriyltris[ω-hydroxy-, benzoate

142104-11-8

2-Butenedioic acid (2E)-, di-C12-15-alkyl esters

142164-39-4

Nickel carbonate hydroxide

142891-20-1

2-Propenoic acid, 2-chloro-3-[2-chloro-5-(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)phenyl]-, ethyl ester, (2Z)-

144377-73-1

4,6-Dioxa-14-aza-10-azonia-5-phosphadotriaconta-23,26-dien-1-aminium, 5-[3-[dimethyl[3-[[(9Z,12Z)-1-oxo-9,12-octadecadien-1-yl]amino]propyl]ammonio]-2-hydroxypropoxy]-2,8-dihydroxy-N,N,10,10-tetramethyl-15-oxo-N-[3-[[(9Z,12Z)-1-oxo-9,12-octadecadien-1-yl]amino]propyl]-, 5-oxide, chloride (1:3), (23Z,26Z)-

144610-93-5

Propanoic acid, 2,2-dimethyl-, tetradecyl ester

146192-98-5

2-Butenedioic acid (2Z)-, monobutyl ester, polymer with ethenyl acetate and 1,7,7-trimethylphenylbicyclo[2.2.1]hept-2-yl 2-propenoate

146632-08-8

Siloxanes and Silicones, di-Me, Bu group- and 3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl group-terminated, polymers with 2-[[(heptadecafluorooctyl)sulfonyl]methylamino]ethyl acrylate and iso-Bu methacrylate

147550-61-6

Copper carbonate hydroxide

148506-50-7

Poly[oxy-1,2-ethanediyl(dimethyliminio)-1,3-propanediylimino(1,6-dioxo-1,6-hexanediyl)imino-1,3-propanediyl(dimethyliminio)-1,2-ethanediyl chloride (1:2)]

148812-63-9

Protein hydrolyzates, wheat, reaction products with palmitoyl chloride

155683-77-5

Oxirane, 2-methyl-, polymer with oxirane, monoisodecyl ether

155715-93-8

Gelatins, polymers with keratin hydrolyzates and L-lysine, hydroxy-N,N,N-trimethyl-1 propanaminium chloride-quaternized

156028-14-7

1H-Imidazolium, 1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-2-undecyl-, inner salt, sodium salt (1:1)

156715-43-4

Protein hydrolyzates, soya, [3-(cocoalklydimethylammonio)-2-hydroxypropyl], chlorides

156798-09-3

Keratins, hydrolyzates, [3-(coco alkyldimethylammonio)-2-hydroxypropyl], chlorides

157009-77-3

9,12-Octadecadienoic acid (9Z,12Z)-, dimer, diisoeicosyl ester

158483-23-9

Poly(oxy-1,2-ethanediyl),α,α',α"-1,2,3-propanetriyltris[ω-hydroxy-,2-hydroxypropanoate

158765-79-8

Micrococcus luteus, lysate

159317-32-5

Acetic acid, hydroxy-, isooctadecyl ester

162030-43-5

Mannopyranuronic acid, 1-O-[hydroxymethyl [[(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)acetyl]oxy]silyl]-

162353-59-5

Quaternary ammonium compounds, (C10-20 and C10-20-unsatd. alkyl) (3-chloro-2-ydroxypropyl) dimethyl, chlorides, reaction products with silk protein hydrolyzates

162888-05-3

Octadecanoic acid, 12-hydroxy-, 16-methylheptadecyl ester

165745-27-7

Carbamic acid, N-butyl-, 3-iodo-2-propyn-1-yl ester, mixt. with N-[1,3-bis(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]-N,N'-bis(hydroxymethyl)urea

169590-61-8

Protein hydrolyzates, silk, [2-hydroxy-3-(trimethylammonio)propyl], chlorides

172376-82-8

6,10-Dodecadienal, 3,7,11-trimethyl-, (6Z)-

173010-79-2

Quaternary ammonium compounds, coco alkyl(2,3-dihydroxypropyl)dimethyl, 3-phosphates (esters), chlorides, sodium salts

173763-15-0

Aluminum Sesquichlorohydrate

175357-18-3

L-Phenylalanine, N-(1-oxo-10-undecen-1-yl)-

175893-70-6

Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, diesters with caroboxymethyl wheat protein hydrolyzates

177080-35-2

Phenol, 4-[(3-hydroxypropyl)amino]-2-nitro-

179005-04-0

Siloxanes and Silicones, 3-[4-[[[3-[(2,3-dihydroxypropyl)dimethylammonio]propyl]amino]carbonyl]-2-oxo-1-pyrrolidinyl]propyl Me, di-Me, 3-[3-[[3-(C8-22-acylamino)propyl]dimethylammonio]-2-hydroxypropyl phosphates], chlorides, sodium salts

182700-78-3

Siloxanes and Silicones, 3-[(3-aminopropyl)amino]propyl Me, di-Me, 3-hydroxypropyl Me, ethoxylated, [(hydroxydimethylsilyl)oxy]-terminated

183476-82-6

L-Ascorbic acid, 2,3,5,6-tetrakis(2-hexyldecanoate)

185018-43-3

L-Ascorbic acid, 2-[(3β)-cholest-5-en-3-yl hydrogen phosphate], monosodium salt

185429-83-8

Ethanone, 1-(1,2,3,4,5,6,7,8-octahydro-1,2,8,8-tetramethyl-2-naphthalenyl)-, cis-

187175-42-4

Silsesquioxanes, Me, hydroxy-terminated, alginate, compds. with caffeine

187991-39-5

L-ascorbic acid, 6-O-(dihydroxymethylsilyl)-

190270-74-7

L-Lysine dihydroxymethylsilyl ester

193888-44-7

1-Propanaminium, N-(carboxymethyl)-2-hydroxy-N-(2-hydroxyethyl)-N-[2-[(1-oxododecyl)amino]ethyl]-3-(phosphonooxy)-, inner salt, monosodium salt

193892-43-2

Poly[oxy(dimethylsilylene)], α-docosyl-ω-(docosyloxy)-

197969-51-0

1-Propanaminium, N,N,N-trimethyl-3-[(2-methyl-1-oxo-2-propen-1-yl)amino]-, chloride (1:1), polymer with methyl 2-propenoate and 2-propenoic acid

198404-98-7

Cyclopropanemethanol, 1-methyl-2-[(1,2,2-trimethylbicyclo[3.1.0]hex-3-yl)methyl]-

205537-77-5

Poly[oxy(dimethylsilylene)], α-hydro-ω-hydroxy-, mixt. with dimethicone

208126-52-7

Resin acids and Rosin acids, mixed esters with dipentaerythritol and 12-hydroxyoctadecanoic acid and stearic acid

208126-56-1

Octadecanoic acid, 12-hydroxy-, mixed esters with dipentaerythritol and isostearic acid

214047-00-4

L-Serine, N2-(1-oxohexadecyl)-L-lysyl-L-threonyl-L-threonyl-L-lysyl-

220119-17-5

Avermectin A1a, 25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-, (5Z)-

220714-63-6

Siloxanes and Silicones, di-Me, 3-hydroxypropyl Me, ethers with polyethylene glycol mono[3-(dimethyloctadecylammonio)-2-hydroxypropyl hydrogen phosphate], inner salts

223717-75-7

Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, ether with methyl D-glucopyranoside (4:1), tri-(9Z)-9-octadecenoate

224948-78-1

Poly(oxy-1,2-ethanediyl),α-[2-[bis(2-aminoethyl)methylammonio]ethyl]-ω-hydroxy-,N,N'-di-C14-18 acyl derivs., Me sulfates (salts)

227200-22-8

L-Ascorbic acid, reaction products with methylsilanetriol and pectin

227605-22-3

Lithium magnesium sodium oxide silicate (Li0.03Mg0.39Na0.07O0.15(Si2O5)0.28)

243133-67-7

Poly(oxy-1,2-ethanediyl), α-(2-hydroxytetradecyl)-ω-hydroxy-,ω-C16-18-alkyl ethers

243137-53-3

Siloxanes and Silicones, di-Me, polymers with mono[(ethenyldimethylsilyl)oxy]-terminated di-Me siloxanes

245443-07-6

L-Glutamic acid, N-(1-oxododecyl)-, mixed (3?)-cholest-5-en-3-yl 2-octyldodecyl esters

246864-39-1

Decanoic acid, 1,2,3-propanetriyl ester, reaction products with polyethylene glycol and 1,2,3-propanetriyl trioctanoate

261713-82-0c

Poly(oxy-1,2ethanediyl),α-(2-hydoxypropyl)-ω-[1-methyl-2-[1-methyl-2-[(1-oxododecyl)oxy]ethoxy]ethoxy-

288839-50-9

1-Octadecanaminium, N,N-dimethyl-N-octyl-, methyl sulfate (1:1)

305812-16-2

Poly(oxy-1,2-ethanediyl),α,α’.,α”.-1,2,3-propanetriyltris [ω-methoxy-

308068-34-0

Glycerides, C16-18 mono-, ethoxylated

308068-94-2

Imidazolium compounds, 2-C12-14-alkyl-1-(carboxymethyl)-4,5-dihydro-1-(2-hydroxyethyl)-, inner salts

308068-97-5

Onium compounds, isoquinolinium, C12-18-alkyl, bromides

308074-11-5

Protein hydrolyzates, compds. with (Z)-N-[3-(dimethylamino)propyl]-9-octadecenamide

321735-39-1

Siloxanes and Silicones, di-Me, 3-hydroxypropyl group- and 3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl group-terminated, polymers with iso-Bu methacrylate

321735-42-6

Siloxanes and Silicones, di-Me, 3-hydroxypropyl group- and 3-[(2-methyl-1-oxo-2-propenyl)oxy]propyl group-terminated, polymers with iso-Bu methacrylate and 2,2,2-trifluoroethyl methacrylate

329925-33-9

Oxacyclopentadec-10-en-2-one, 13-methyl-

345648-01-3

1-Propanaminium N- (3-aminopropyl) -2,3-dihydroxy-N,N-dimethyl-,N-limnanthes alba seed-oil acyl derivs., chlorides

348120-88-7

Hexanoic acid, 3,5,5 -trimethyl-, octadecyl ester

642072-46-6

Ethanol, 2,2'-iminobis-,compd. with α-sulfo-ω-(tetradecyloxy)poly(oxy-1,2-ethanediyl)

827596-80-5

Octadecanoic acid, 12-hydroxy-, polymer with oxirane, triblock

869734-19-0

acids, Cannabis sativa seed-oil, esters with polyethylene glycol ether with glycerol (3:1)

1007304-55-3

Poly(oxy-1,2-ethanediyl), ω'-hydroxy-ω-[(1- oxoisooctadecyl)oxy]-ω''-[[(5-oxo-2-pyrrolidinyl)carbonyl]oxy]- α,α',α''-1,2,3-propanediyltris-

1034015-50-3

Polysaccharides, sugarcane, 3-(dimethyloctadecylammonio)-2-hydroxypropyl ethers, chlorides

1072005-10-7

Decanoic acid, mixed diesters with octanoic acid and 1,3-propanediol

1384982-80-2

Quaternary Ammonium Compounds, dimethylbis (mixed C12-15-alkyl and cetyl and stearyl), chlorides

1429320-75-1

Butanedioic acid, 2-sulfo-, 1(or 4)-C10-16-alkyl esters, disodium salts

a This substance was erroneously identified as CAS RN 139096-04-1 in Part 4 of Schedule 1 of the mandatory survey that was issued pursuant to section 71 of CEPA, as published in the Canada Gazette, Part I in January 2017 (Canada Gazette 2017). The correct CAS RN is listed in the table, namely CAS RN 60662-14-8.

b The name of this substance was misspelled in Part 4 of Schedule 1 of the mandatory survey that was issued pursuant to section 71 of CEPA, as published in the Canada Gazette, Part I in January 2017 (Canada Gazette 2017), namely “Siloxanes and Silicones, a-D-mannopyranuronoyloxy Me, hydroxy-terminated”. The correct name is provided in the table, namely “Siloxanes and Silicones, α-D-mannopyranuronoyloxy Me, hydroxy-terminated”.

c This substance was erroneously identified as “Poly(oxy-1,2ethanedily),α(2-hydoxypropyl)-w-[1-methyl-2-[(1-oxododecyl)oxy]ethoxy]ethoxy-(9Cl)” in Part 4 of Schedule 1 of the mandatory survey that was issued pursuant to section 71 of CEPA, as published in the Canada Gazette, Part I in January 2017 (Canada Gazette 2017). The correct substance name is provided in the table, namely “Poly(oxy-1,2-ethanediyl), α-(2-hydroxypropyl)-ω-[1-methyl-2-[1-methyl-2-[(1-oxododecyl)oxy]ethoxy]ethoxy]-”.

Appendix B

Active pharmaceutical substances proposed for removal from the R-ICL based on them having never been marketed, being discontinued or approved for limited use in Canada according to information in Health Canada records

The Chemical Abstracts Service (CAS) Registry Number (CAS RN)

Substance name

51-15-0

Pyridinium, 2-[(hydroxyimino)methyl]-1-methyl-, chloride

59-46-1

Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester

60-41-3

Strychnidin-​10-​one, sulfate (2:1)

63-89-8

3,​5,​9-​Trioxa-​4-​phosphapentacosan-​1-​aminium, 4-​hydroxy-​N,​N,​N-​trimethyl-​10-​oxo-​7-​[(1-​oxohexadecyl)​oxy]​-​, inner salt, 4-​oxide, (7R)​-

64-73-3

2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, monohydrochloride, (4S,4aS,5aS,6S,12aS)-

71-81-8

Benzenepropanaminium, γ-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-γ-phenyl-, iodide

83-73-8

8-​Quinolinol, 5,​7-​diiodo-

86-75-9

8-​Quinolinol, 8-​benzoate

90-39-1

7,​14-​Methano-​2H,​6H-​dipyrido[1,​2-​a:1',​2'-​e]​[1,​5]​diazocine, dodecahydro-​, (7S,​7aR,​14S,​14aS)​-

96-83-3

Benzenepropanoic acid, 3-​amino-​α-​ethyl-​2,​4,​6-​triiodo-

103-16-2

Phenol, 4-​(phenylmethoxy)​-

115-76-4

1,3-Propanediol, 2,2-diethyl-

126-27-2

Acetamide, 2,​2'-​[(2-​hydroxyethyl)​imino]​bis[N-​(1,​1-​dimethyl-​2-​phenylethyl)​-​N-​methyl-

138-39-6

Benzenesulfonamide, 4-(aminomethyl)-

299-39-8

7,​14-​Methano-​2H,​6H-​dipyrido[1,​2-​a:1',​2'-​e]​[1,​5]​diazocine, dodecahydro-​, (7S,​7aR,​14S,​14aS)​-​, sulfate (1:1)

302-96-5

1'H-Androstano[3,2-c]pyrazol-17-ol, 17-methyl-, ((5α,​17β)-

316-42-7

2H-​Benzo[a]​quinolizine, 3-​ethyl-​1,​3,​4,​6,​7,​11b-​hexahydro-​9,​10-​dimethoxy-​2-​[[(1R)​-​1,​2,​3,​4-​tetrahydro-​6,​7-​dimethoxy-​1-​isoquinolinyl]​methyl]​-​, hydrochloride (1:2)​, (2S,​3R,​11bS)​-

357-07-3

Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, hydrochloride, (5α)-

481-06-1

Naphtho[1,​2-​b]​furan-​2,​8(3H,​4H)​-​dione, 3a,​5,​5a,​9b-​tetrahydro-​3,​5a,​9-​trimethyl-​, (3S,​3aS,​5aS,​9bS)​-

483-18-1

 2H-Benzo[a]quinolizine, 3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-[[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]methyl]-, (2S,3R,11bS)-

491-58-7

9(10H)-Anthracenone, 1,8-dihydroxy-3-methyl-

513-10-0

Ethanaminium, 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethyl-, iodide

522-40-7

 Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis-, 1,1'-bis(dihydrogen phosphate)

552-94-3

Benzoic acid, 2-​hydroxy-​, 2-​carboxyphenyl ester

644-62-2

Benzoic acid, 2-​[(2,​6-​dichloro-​3-​methylphenyl)​amino]​-

645-05-6

1,​3,​5-​Triazine-​2,​4,​6-​triamine, N2,​N2,​N4,​N4,​N6,​N6-​hexamethyl-

977-79-7

Pregna-​4,​6-​diene-​3,​20-​dione, 6,​17-​dimethyl-

1176-08-5

Ethanamine, N,​N-​dimethyl-​2-​[2-​(phenylmethyl)​phenoxy]​-​, 2-​hydroxy-​1,​2,​3-​propanetricarboxylat​e (1:1)

1415-73-2

9(10H)​-​Anthracenone, 10-​β-​D-​glucopyranosyl-​1,​8-​dihydroxy-​3-​(hydroxymethyl)​-​, (10S)​-

1953-02-2

Glycine, N-​(2-​mercapto-​1-​oxopropyl)​-

1972-08-3

6H-​Dibenzo[b,​d]​pyran-​1-​ol, 6a,​7,​8,​10a-​tetrahydro-​6,​6,​9-​trimethyl-​3-​pentyl-​, (6aR,​10aR)​-

2152-34-3

 2-amino-5-phenyl-1,3-oxazol-4-one

2451-01-6

Cyclohexanemethanol, 4-hydroxy-α,α,4-trimethyl-, monohydrate, cis-

3385-03-3

Pregna-​1,​4-​diene-​3,​20-​dione, 6-​fluoro-​11,​21-​dihydroxy-​16,​17-​[(1-​methylethylidene)​bis(oxy)​]​-​, (6α,​11β,​16α)​-

3902-71-4

7H-​Furo[3,​2-​g]​[1]​benzopyran-​7-​one, 2,​5,​9-​trimethyl-

4419-92-5

Benzoic acid, 2-​hydroxy-​, compd. with N-​ethylethanamine (1:1)

4697-14-7

4-​Thia-​1-​azabicyclo[3.2.0]​heptane-​2-​carboxylic acid, 6-​[[2-​carboxy-​2-​(3-​thienyl)​acetyl]​amino]​-​3,​3-​dimethyl-​7-​oxo-​, sodium salt (1:2)​, (2S,​5R,​6R)​-

5175-83-7

Phenol, 2,​4,​6-​tribromo-​, bismuth(3+) salt (3:1)

5588-33-0

10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfinyl)-

5714-73-8

Glycine, N-​benzoyl-​, compd. with 1,​3,​5,​7-​tetraazatricyclo[3.3​.1.13,​7]​decane (1:1)

5936-28-7

1(3H)-Isobenzofuranone, 6,7-dimethoxy-3-[(5R)-5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-, hydrochloride, (3S)-

7187-62-4

Quinolinium, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-

7492-32-2

Benzenepropanaminium​, γ-​(aminocarbonyl)​-​N-​methyl-​N,​N-​bis(1-​methylethyl)​-​γ-​phenyl-

7732-97-0

Estra-1,3,5(10)-triene-3,17-diol (17β)-, diheptanoate

8015-61-0

Aloin

9002-64-6

Parathormone

9006-52-4

Tannins, albumin complexes

9039-53-6

Kinase (enzyme-activating), uro-

10417-86-4

Pregnane-​3,​11,​20-​trione, 21-​hydroxy-​, (5β)​-

10418-03-8

2'H-​Androst-​2-​eno[3,​2-​c]​pyrazol-​17-​ol, 17-​methyl-​, (5α,​17β)​-

11116-97-5

Calcium, (D-gluconato)(2-hydroxypropanoato)-

13103-34-9

Androsta-​1,​4-​dien-​3-​one, 17-​[(1-​oxo-​10-​undecenyl)​oxy]​-​, (17β)​-

13412-64-1

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, (2S,5R,6R)-

13838-16-9

Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-

13870-90-1

Cobinamide, Co-​(5'-​deoxyadenosin-​5'-​yl)​-​, f-​(dihydrogen phosphate)​, inner salt, 3'-​ester with (5,​6-​dimethyl-​1-​α-​D-​ribofuranosyl-​1H-​benzimidazole-​κN3)

14028-44-5

Dibenz[b,​f]​[1,​4]​oxazepine, 2-​chloro-​11-​(1-​piperazinyl)​-

14769-73-4

Imidazo[2,​1-​b]​thiazole, 2,​3,​5,​6-​tetrahydro-​6-​phenyl-​, (6S)​-

15686-51-8

Pyrrolidine, 2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, (2R)-

20537-88-6

Ethanethiol, 2-​[(3-​aminopropyl)​amino]​-​, 1-​(dihydrogen phosphate)

20559-55-1

Carbamic acid, (5-propoxy-1H-benzimidazol-2-yl)-, methyl ester

21256-18-8

2-​Oxazolepropanoic acid, 4,​5-​diphenyl-

22194-22-5

Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-, (2R)-

23288-49-5

Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-

29457-07-6

4-​Thia-​1-​azabicyclo[3.2.0]​heptane-​2-​carboxylic acid, 6-​[[(2R)​-​2-​carboxy-​2-​(3-​thienyl)​acetyl]​amino]​-​3,​3-​dimethyl-​7-​oxo-​, sodium salt (1:2)​, (2S,​5R,​6R)​-

32093-35-9

 Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6S)-, phosphate (1:1)

33089-61-1

 Methanimidamide, N'-(2,4-dimethylphenyl)-N-[[(2,4-dimethylphenyl)imino]methyl]-N-methyl-

35711-34-3

1H-​Pyrrole-​2-​acetic acid, 1-​methyl-​5-​(4-​methylbenzoyl)​-​, sodium salt (1:1)

37203-87-5

Formaldehyde, mixt. with methylphenol

37270-89-6

Heparin, calcium salt

38916-34-6

Somatostatin (sheep)

40958-31-4

Somatostatin (sheep reduced)

42116-76-7

Carbamothioic acid, N-​[2-​(2-​methyl-​5-​nitro-​1H-​imidazol-​1-​yl)​ethyl]​-​, O-​methyl ester

49697-38-3

Androsta-​1,​4-​dien-​3-​one, 11-​hydroxy-​16,​17-​dimethyl-​17-​(1-​oxopropyl)​-​, (11β,​16α,​17β)​-

50679-08-8

1-​Piperidinebutanol, α-​[4-​(1,​1-​dimethylethyl)​phenyl]​-​4-​(hydroxydiphenylmeth​yl)​-

52128-35-5

2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-

54527-84-3

3,​5-​Pyridinedicarboxylic acid, 1,​4-​dihydro-​2,​6-​dimethyl-​4-​(3-​nitrophenyl)​-​, 3-​methyl 5-​[2-​[methyl(phenylmethyl​)​amino]​ethyl] ester, hydrochloride (1:1)

56211-40-6

3-​Pyridinesulfonamide, N-​[[(1-​methylethyl)​amino]​carbonyl]​-​4-​[(3-​methylphenyl)​amino]​-

56767-76-1

[1,​1'-​Biphenyl]​-​4-​acetic acid, 2-​fluoro-​α-​methyl-​, sodium salt (1:1)

59708-52-0

4-Piperidinecarboxylic acid, 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-, methyl ester

60106-89-0

2-​Propanol, 1-​[(1-​methylethyl)​amino]​-​3-​(2-​propylphenoxy)​-

64211-45-6

Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (1Z)-

65473-14-5

1-​Naphthalenemethanami​ne, N-​methyl-​N-​[(2E)​-​3-​phenyl-​2-​propen-​1-​yl]​-​, hydrochloride (1:1)

65899-73-2

1H-​Imidazole, 1-​[2-​[(2-​chloro-​3-​thienyl)​methoxy]​-​2-​(2,​4-​dichlorophenyl)​ethyl]​-

68373-14-8

4-​Thia-​1-​azabicyclo[3.2.0]​heptane-​2-​carboxylic acid, 3,​3-​dimethyl-​7-​oxo-​, 4,​4-​dioxide, (2S,​5R)​-

68401-82-1

5-​Thia-​1-​azabicyclo[4.2.0]​oct-​2-​ene-​2-​carboxylic acid, 7-​[[(2Z)​-​2-​(2-​amino-​4-​thiazolyl)​-​2-​(methoxyimino)​acetyl]​amino]​-​8-​oxo-​, sodium salt (1:1)​, (6R,​7R)​-

68844-77-9

1H-​Benzimidazol-​2-​amine, 1-​[(4-​fluorophenyl)​methyl]​-​N-​[1-​[2-​(4-​methoxyphenyl)​ethyl]​-​4-​piperidinyl]​-

69712-56-7

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7S)-

71109-09-6

1-​Naphthaleneacetic acid, 4-​cyclohexyl-​α-​methyl-

82030-87-3

Somatotropin (human)​, N-​L-​methionyl-

82752-99-6

3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, monohydrochloride

87233-61-2

 1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-

94218-72-1

Interleukin 2 (human clone pTIL2-​21a protein moiety)

96684-40-1

β-​Cyclodextrin, compd. with 4-​hydroxy-​2-​methyl-​N-​2-​pyridinyl-​2H-​1,​2-​benzothiazine-​3-​carboxamide 1,​1-​dioxide (5:2)

98530-76-8

Blood-​coagulation factor XIVa (human protein moiety)

105816-04-4

D-​Phenylalanine, N-​[[trans-​4-​(1-​methylethyl)​cyclohexyl]​carbonyl]​-

107753-78-6

Carbamic acid, N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester

112362-50-2

3H-21,18-Nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone, 26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-4,12-dimethyl-3-(1-methylethyl)-, (3R,4R,5E,10E,12E,14S,26R,26aS)-

115956-13-3

1H-Indole-3-carboxylic acid, (6R,9aS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate (1:1) (CAS name to be changed)

118390-30-0

Interferon α1 (human lymphoblast reduced), N-L-methionyl-22-L-arginine-76-L-alanine-78-L-aspartic acid-79-L-glutamic acid-86-L-tyrosine-90-L-tyrosine-156-L-threonine-157-L-asparagine-158-L-leucine-

120138-50-3

Virginiamycin S1, 4-[4-(dimethylamino)-N-methyl-L-phenylalanine]-5-[(2S,5R)-5-[[[(3S)-1-azabicyclo[2.2.2]oct-3-yl]thio]methyl]-4-oxo-2-piperidinecarboxylic acid]-

120373-24-2

5-​Heptenoic acid, 7-​[(1R,​2R,​3R,​5S)​-​3,​5-​dihydroxy-​2-​(3-​oxodecyl)​cyclopentyl]​-​, 1-​methylethyl ester, (5Z)​-

125494-59-9

Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, hydrate (1:1:1)

133652-38-7

173-527-Plasminogen activator (human tissue-type), 173-L-serine-174-L-tyrosine-175-L-glutamine-

133814-18-3

Isoquinolinium, 2,2'-[(1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, (1R,1'S,2S,2'R)-rel-

133814-19-4

Isoquinolinium, 2,2'-[[(4E)-1,8-dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, (1R,1'R)-

136279-32-8

Interleukin 2 (human)​, N-​L-​methionyl-

138068-37-8

Hirudin (Hirudo medicinalis isoform HV1), 1-L-leucine-2-L-threonine-63-desulfo-

140678-14-4

Manganate(6-), [[N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-κO)-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycinato-κN,​κO]](8-)]-, trisodium trihydrogen, (OC-6-13)-

143201-11-0

6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)-

143653-53-6

Immunoglobulin G1, anti-​(human integrin αIIbβ3) Fab fragment (human-​mouse monoclonal c7E3 clone p7E3VHhCγ1 γ1-​chain)​, disulfide with human-​mouse monoclonal c7E3 clone p7E3VκhCκ κ-​chain

144025-09-2

1H-​Imidazole, 1-​[2-​[(2-​chloro-​3-​thienyl)​methoxy]​-​2-​(2,​4-​dichlorophenyl)​ethyl]​-​, (-​)​-

147059-72-1

1,​8-​Naphthyridine-​3-​carboxylic acid, 7-​[(1α,​5α,​6α)​-​6-​amino-​3-​azabicyclo[3.1.0]​hex-​3-​yl]​-​1-​(2,​4-​difluorophenyl)​-​6-​fluoro-​1,​4-​dihydro-​4-​oxo-

147221-93-0

 Methanesulfonamide, N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-, methanesulfonate (1:1)

150378-17-9

D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-

152923-56-3

Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal clone 1H4 γ1-​chain), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer

153259-65-5

Cyclohexanecarboxyli​c acid, 4-​cyano-​4-​[3-​(cyclopentyloxy)​-​4-​methoxyphenyl]​-​, cis-

153559-49-0

Benzoic acid, 4-​[1-​(5,​6,​7,​8-​tetrahydro-​3,​5,​5,​8,​8-​pentamethyl-​2-​naphthalenyl)​ethenyl]​-

162011-90-7

2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-

163545-26-4

1-165-Hematopoietic cell growth factor KL (human clone V19.8:hSCF162), N-L-methionyl-, dimer

165101-51-9

Becaplermin

173937-91-2

3-​Pyrrolidinecarboxyli​c acid, 4-​(1,​3-​benzodioxol-​5-​yl)​-​1-​[2-​(dibutylamino)​-​2-​oxoethyl]​-​2-​(4-​methoxyphenyl)​-​, (2R,​3R,​4S)​-

191114-48-4

2H-​Oxacyclotetradecino[​4,​3-​d]​oxazole-​2,​6,​8,​14(1H,​7H,​9H)​-​tetrone, 4-​ethyloctahydro-​11-​methoxy-​3a,​7,​9,​11,​13,​15-​hexamethyl-​1-​[4-​[4-​(3-​pyridinyl)​-​1H-​imidazol-​1-​yl]​butyl]​-​10-​[[3,​4,​6-​trideoxy-​3-​(dimethylamino)​-​β-​D-​xylo-​hexopyranosyl]​oxy]​-​, (3aS,​4R,​7R,​9R,​10R,​11R,​13R,​15R,​15aR)​-

215647-85-1

Interferon α-​2b (human)​, pegylated

219989-84-1

(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2 (2-methylthiazol-4-yl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione

706808-37-9

[29-tyrosine,104-glutamic acid] CTLA-4 (antigen) (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1(human monoclonal Fc domain-containing fragment), bimol. (120120')-disulfide

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: